Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
629
mi
from 43215
Fridley, MN
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
629
mi
from 43215
Fridley, MN
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
549
mi
from 43215
Stony Brook, NY
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1069
mi
from 43215
Austin, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
987
mi
from 43215
College Station, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
987
mi
from 43215
College Station, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
273
mi
from 43215
Lynchburg, VA
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
273
mi
from 43215
Lynchburg, VA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
1972
mi
from 43215
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
2102
mi
from 43215
Palo Alto, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
2102
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
545
mi
from 43215
Farmington, CT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
545
mi
from 43215
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
164
mi
from 43215
Ann Arbor, MI
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Rutgers Robert Wood Johnson Medical School
455
mi
from 43215
New Brunswick, NJ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Rutgers Robert Wood Johnson Medical School
455
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Medical Center
524
mi
from 43215
Charleston, SC
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Medical Center
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from 43215
Houston, TX
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Utah Health Care
1513
mi
from 43215
Salt Lake City, UT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Utah Health Care
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Liverpool Hospital
9473
mi
from 43215
Liverpool,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Liverpool Hospital
9473
mi
from 43215
Liverpool,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
328
mi
from 43215
Washington,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
707
mi
from 43215
Mobile, AL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
707
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
656
mi
from 43215
Rogers, AR
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
656
mi
from 43215
Rogers, AR
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
2043
mi
from 43215
Sacramento, CA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
992
mi
from 43215
Miami, FL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
978
mi
from 43215
Miramar, FL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
978
mi
from 43215
Miramar, FL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
463
mi
from 43215
Newnan, GA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
463
mi
from 43215
Newnan, GA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
187
mi
from 43215
Louisville, KY
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
187
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1330
mi
from 43215
Albuquerque, NM
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1330
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
320
mi
from 43215
High Point, NC
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
320
mi
from 43215
High Point, NC
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
130
mi
from 43215
Beachwood, OH
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
130
mi
from 43215
Beachwood, OH
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
2029
mi
from 43215
Portland, OR
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
2029
mi
from 43215
Portland, OR
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
11
mi
from 43215
Chomutov,
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
11
mi
from 43215
Chomutov,
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1947
mi
from 43215
San Diego, CA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (8568)
442
mi
from 43215
New York, NY
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (8568)
442
mi
from 43215
New York, NY
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
280
mi
from 43215
Knoxville, TN
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
280
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated:  12/31/1969
Sylvester Comprenhensive Cancer Center
992
mi
from 43215
Miami, FL
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated: 12/31/1969
Sylvester Comprenhensive Cancer Center
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital dermatology clinics
992
mi
from 43215
Miami, FL
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital dermatology clinics
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
Status: Enrolling
Updated:  12/31/1969
UCSF Dermatology
1982
mi
from 43215
San Francisco, CA
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
Status: Enrolling
Updated: 12/31/1969
UCSF Dermatology
1982
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #129)
1982
mi
from 43215
Encino, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #129)
1982
mi
from 43215
Encino, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #136)
1982
mi
from 43215
Los Angeles, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #136)
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #147)
2041
mi
from 43215
Sacramento, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #147)
2041
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #123)
1950
mi
from 43215
San Diego, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #123)
1950
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #123)
1950
mi
from 43215
San Diego, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #123)
1950
mi
from 43215
San Diego, CA
Click here to add this to my saved trials